Paige vs Proscia (2026)
Paige sells algorithms; Proscia sells the platform algorithms run on, so a laboratory may well buy both. Paige Prostate holds a De Novo authorization (DEN200080) as an adjunct for prostate biopsies, and Paige sells further suites and the Virchow foundation models; Tempus acquired it in August 2025. Proscia's Concentriq AP-Dx is 510(k) cleared for primary diagnosis on FFPE surgical slides (K230839, and K261380 in August 2026, which added cloud deployment and a change control plan), Health Canada licensed and CE marked under the IVDR. Proscia's own AI applications are research use only, and more than 230 applications from Proscia and other makers run on the platform under their makers' labeling.
- You are buying a detection algorithm with an authorization that covers the AI.
- Prostate biopsy review is the first workflow you want AI to support.
- Foundation models for your own development work matter to you.
- You are going digital and need a cleared platform for primary diagnosis first.
- You want to run many makers' applications, on a platform that supports more than 45 scanners.
- Your security review asks for named certifications: Proscia states ISO 27001, ISO 13485 and SOC 2 Type II.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Paige and Proscia are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Paige | Proscia |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2018 | 2014 |
| Headquarters | New York, New York, United States | Philadelphia, Pennsylvania, United States |
| Website | paige.ai | proscia.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Paige
-
Product / capability
Paige launched an AI tool that screens 505 genes directly from H and E stained pathology slides, without requiring next generation sequencing as a first step.
Source
Proscia
-
Regulatory / FDA
Proscia received a new FDA 510(k) clearance for its Concentriq AP-Dx digital pathology platform.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Computational pathology company that produced the first FDA authorized AI based digital pathology product: Paige Prostate received De Novo authorization (DEN200080) in September 2021 as an adjunct that flags the area of a digitized prostate biopsy most likely to contain cancer, used with a specified scanner and the company's FullFocus viewer.
Source: AI Health Index, September 2026
Digital pathology software company whose Concentriq platform manages, displays and analyzes whole slide pathology images for clinical laboratories and life sciences organizations. Its diagnostic edition, Concentriq AP-Dx, is FDA 510(k) cleared (K230839 in 2024 and K261380 in August 2026, which added cloud deployment and a change control plan), Health Canada licensed and CE marked under the EU IVDR for primary diagnosis on FFPE surgical pathology slides; the research editions are labeled Research Use Only, a distinction the company draws explicitly.
Source: AI Health Index, September 2026
Questions buyers ask
How do Paige and Proscia work with the EHR?
Paige ships its own viewing and case management layer, the FDA cleared FullFocus viewer and the FullFolio image management system, as a turnkey option, and states that its applications also run inside partner digital pathology platforms, so a laboratory that already runs an image management system need not replace it.
With Proscia, the company states that AI recommended ancillary test requests flow back into the LIS rather than a separate ticket queue, which is a real workflow closure rather than a display feature. The platform also serves as a host environment for third party algorithms, with at least one external spatial biology vendor embedding its predictive biomarker technology into Concentriq. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Paige and Proscia handle patient data?
Paige's privacy policy is scoped to the company's websites and online services, and the personal information it lists is business and website contact data collected through analytics and marketing tools; it does not describe what happens to the whole slide images a laboratory processes through the Paige Platform or Alba.
For Proscia, the platform page states that "everything in Concentriq stays within your organization, unless you give express permission to de-identify and share it to advance research", and that "your data is never used to train the models Concentriq runs". From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Paige and Proscia cover?
With Paige, the company sells suites for prostate, breast, gastrointestinal and pan cancer pathology to clinical pathology laboratories, and, through Tempus, reaches precision oncology programs. Paige Prostate's authorization names its setting precisely: digitized prostate biopsy images from the Philips Ultra Fast Scanner, viewed in FullFocus, as an adjunct to the pathologist's review.
In Proscia's case, the clinical edition serves high volume diagnostic laboratories for primary diagnosis on scanned surgical pathology slides from FFPE tissue, and excludes frozen sections, cytology and non-FFPE hematopathology specimens; the research editions serve life sciences organizations for biomarker research, clinical trials and companion diagnostics. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Paige and Proscia?
For Paige, the current home page cites no study, customer outcome or deployment figure for any suite.
With Proscia, the earlier dermatopathology classifier was validated across two university hospitals and two commercial dermatopathology laboratories on more than 20,000 biopsy slides. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
These sit at different layers. Paige's current site does not state the regulatory status of each suite, and Proscia does not warrant third party applications that run on its platform. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.